Page last updated: 2024-11-04

rolipram and Lung Diseases, Obstructive

rolipram has been researched along with Lung Diseases, Obstructive in 4 studies

Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.

Research Excerpts

ExcerptRelevanceReference
"Using a rat model of lipopolysaccharide (LPS)-induced pulmonary inflammation, the antiinflammatory activity of SB 207499 was evaluated and compared to that of the prototypic type-4 phosphodiesterase (PDE4) inhibitor, rolipram."3.71Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. ( Chapman, R; Fine, J; Jones, H; Kreutner, W; Kung, TT; Minnicozzi, M; Spond, J, 2001)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rickards, KJ2
Page, CP2
Lees, P2
Gettinby, G1
Cunningham, FM2
Dal Piaz, V1
Giovannoni, MP1
Spond, J1
Chapman, R1
Fine, J1
Jones, H1
Kreutner, W1
Kung, TT1
Minnicozzi, M1

Reviews

1 review available for rolipram and Lung Diseases, Obstructive

ArticleYear
Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
    European journal of medicinal chemistry, 2000, Volume: 35, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Arthritis, Rheumatoid; Asthma; Cyclic Nucleotide Phosphodiester

2000

Other Studies

3 other studies available for rolipram and Lung Diseases, Obstructive

ArticleYear
In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood.
    Journal of veterinary pharmacology and therapeutics, 2003, Volume: 26, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Res

2003
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
    Pulmonary pharmacology & therapeutics, 2001, Volume: 14, Issue:2

    Topics: Adrenalectomy; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Humans; Inflammation; I

2001
Differential inhibition of equine neutrophil function by phosphodiesterase inhibitors.
    Journal of veterinary pharmacology and therapeutics, 2001, Volume: 24, Issue:4

    Topics: Animals; Cell Adhesion; Cells, Cultured; Horse Diseases; Horses; Lung Diseases, Obstructive; Neutrop

2001